Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Parissa Alerasool"'
Autor:
Qian Qin, Tomi Jun, Bo Wang, Vaibhav G. Patel, George Mellgard, Xiaobo Zhong, Mahalya Gogerly-Moragoda, Anish B. Parikh, Amanda Leiter, Emily J. Gallagher, Parissa Alerasool, Philip Garcia, Himanshu Joshi, MBBS, Matthew Galsky, William K. Oh, Che-Kai Tsao
Publikováno v:
Discover Oncology, Vol 13, Iss 1, Pp 1-11 (2022)
Abstract Objectives Response to immune checkpoint inhibitor (ICI) remains limited to a subset of patients and predictive biomarkers of response remains an unmet need, limiting our ability to provide precision medicine. Using real-world data, we aimed
Externí odkaz:
https://doaj.org/article/37da49ca41554ae38f0bb80d40f404bf
Autor:
David Ambinder, Monica He, Pressler Mariel, Parissa Alerasool, Daniel Bassily, Akhil Saji, Evan Spencer, Majid Eshghi, Muhammad Choudhury, John Phillips
Publikováno v:
Journal of Urology. 209
Autor:
George Mellgard, Vaibhav G. Patel, Xiaobo Zhong, Himanshu Joshi, Qian Qin, Bo Wang, Anish Parikh, Tomi Jun, Parissa Alerasool, Philip Garcia, Mahalya Gogerly-Moragoda, Amanda Leiter, Emily J Gallagher, William K. Oh, Matthew D. Galsky, Che-Kai Tsao
Publikováno v:
Journal of Cancer Research and Clinical Oncology.
Purpose: Stress-induced adrenergic signaling can suppress the immune system. In animal models, pharmacological beta-blockade stimulates CD8+ T-cell activity and improves clinical activity of immune checkpoint blockade (ICB) in inhibiting tumor growth
Autor:
Vadim S. Koshkin, Bernadett Szabados, Daniel Castellano, Matthew D. Galsky, Petros Grivas, Lucia Carril-Ajuria, Min Y. Teo, Daniele Raggi, Guru Sonpavde, Parissa Alerasool, Thomas Powles, Lillian Werner, Jacob Gaines, Xiao X. Wei, Ravindran Kanesvaran, Joaquim Bellmunt, Jonathan E. Rosenberg, Andrea Necchi, Noah M. Hahn, Rana R. McKay, Laura Morrison, Pedro Isaacsson Velho
Publikováno v:
J Urol
PURPOSE: Current first-line treatment options in patients with metastatic urothelial carcinoma (mUC) unfit to receive cisplatin-containing chemotherapy include PD-1/L1 inhibitors and carboplatin-containing chemotherapy. However, the optimal sequencin
Autor:
Matthew D. Galsky, Ming Yin, Xiaobo Zhong, Amanda Leiter, Amir Mortazavi, Philip Garcia, Steven K. Clinton, Parissa Alerasool, Qian Qin, George Mellgard, Bo Wang, Vaibhav G. Patel, Anish B. Parikh, William Oh, Emily J. Gallagher, Yuanquan Yang, Che-Kai Tsao, Edmund Folefac, Paul Monk
Publikováno v:
Am J Clin Oncol
Objectives Immune checkpoint inhibitors (ICIs) are being increasingly used across cancer types. Emergency room (ER) and inpatient (IP) care, common in patients with cancer, remain poorly defined in this specific population, and risk factors for such
Publikováno v:
World Journal of Urology. 39:1319-1329
Patients harboring high-grade non-muscle-invasive bladder cancer (NMIBC) experience high rates of both recurrence and progression. Currently, few treatment options besides cystectomy exist for this at-risk population, especially those with BCG-unresp
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
William Oh, Amanda Leiter, Philip Garcia, Emily Carroll, Anish B. Parikh, Jennifer Ben Shimol, Danielle Brooks, Elliot Eisenberg, Matthew D. Galsky, Bo Wang, Emily J. Gallagher, Che-Kai Tsao, Suraj K. Jaladanki, Parissa Alerasool, George Mellgard, Qian Qin, Vaibhav G. Patel
Publikováno v:
Journal of Clinical Oncology. 38:480-480
480 Background: Immune related adverse events (IRAEs) with immune checkpoint inhibitor (ICI) therapy are well recognized, but predictors for IRAEs are not well defined. We aim to characterize the type, timing, and clinical risk factors associated wit
Autor:
George Mellgard, Danielle Brooks, Qian Qin, Jennifer Ben Shimol, Amanda Leiter, Vaibhav G. Patel, Che-Kai Tsao, Suraj K. Jaladanki, Philip Garcia, William Oh, Parissa Alerasool, Anish B. Parikh, Matthew D. Galsky, Elliot Eisenberg, Bo Wang, Emily Carroll, Emily J. Gallagher
Publikováno v:
Journal of Clinical Oncology. 38:482-482
482 Background: Despite the widespread use of immune checkpoint inhibitors (ICIs), patterns of disease progression (POD) are poorly characterized. We aim to define these characteristics in patients (pts) with advanced urothelial carcinoma (UC) and re
Autor:
Ahmad Manbohi, Seyed Ali Mousavi Shaegh, Thomas Shupe, Anthony Atala, Yu Shrike Zhang, Duckjin Kim, Colin E. Bishop, Mehmet R. Dokmeci, Antonia Silvestri, Huseyin Avci, Sukyoung Chae, Su Ryon Shin, Noor Shaikh, Aleksander Skardal, João Ribas, Parissa Alerasool, Giovanni Calzone, Alessandro Polini, Solange Massa, Weijia Zhang, Ali Khademhosseini, Tugba Kilic, Ning Hu, Erica Budina, Reza Riahi, Amir Sanati Nezhad, Jian Kang, Julio Aleman, Fabio De Ferrari, Adel Pourmand, Nupura S. Bhise
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America. 114(12)
Organ-on-a-chip systems are miniaturized microfluidic 3D human tissue and organ models designed to recapitulate the important biological and physiological parameters of their in vivo counterparts. They have recently emerged as a viable platform for p